New Data For Linagliptin Show Clinically Meaningful Efficacy Similar To Glimepiride But With Fewer Cardiovascular Events
Links shared publicly online about this topic.
- 188total visits
New Data For Linagliptin Show Clinically Meaningful Efficacy Similar To Glimepiride But With Fewer Cardiovascular Events
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced Phase III study results for linagliptin (proposed trade name Trajenta® in Europe), demonstrating improved glycaemic c
View full resource at medicalnewstoday.com
Tags: Heart, Diabetes Type 2 Medication, Diabetes Medication, Amaryl, Eli Lilly and Company, Boehringer Ingelheim, Event
Most Recently Shared on June 27, 2011 at 2:05 pm By:
New Data For Linagliptin Show Clinically Meaningful Efficacy Similar To Glimepiride But With Fewer Cardiovascular Events http://mnt.to/3XGQ
Advertisement
